In the context of advanced neuroblastoma, the downregulation of sVEGFR2 is correlated with the disease progression.148 Furthermore, an anti-VEGFD monoclonal antibody, cVE199, specifically binds VEGFD to inhibit the binding of VEGFD to VEGFR3, thereby significantly reducing the lymphangiogenesis in the context of primary lesions.149. This evidence concerns the gene VEGFD and neuroblastoma.